Evenity (Romosozumab) Cost in Wisconsin: Pricing, Insurance, and Savings in 2026

What Does Evenity (Romosozumab) Actually Cost in Wisconsin?

The Amgen/UCB wholesale acquisition cost for Evenity sits at $1,825 per monthly injection in 2026, and that number holds steady across Wisconsin retail pharmacies as the average cash-pay price. A full 12-month treatment course runs approximately $21,900 before any insurance or discount. Each monthly dose consists of two prefilled syringes (105 mg each, for a total of 210 mg), administered subcutaneously by a healthcare provider or trained self-injector.

List Price vs. What You Actually Pay

The $1,825 figure is the sticker price. Very few patients pay it. Your actual cost depends on three variables: insurance type, prior authorization status, and whether you use a manufacturer savings program. Commercially insured patients with specialty pharmacy benefits often see copays between $0 and $150 per month after the savings card is applied. Uninsured patients face the full $1,825 unless they qualify for Amgen's patient assistance program.

Price Comparison Across Wisconsin Pharmacies

Specialty pharmacies in Milwaukee, Madison, and Green Bay typically match the $1,825 list price for cash-pay customers. There is minimal price variation because Evenity is a specialty biologic distributed through limited pharmacy networks. Unlike small-molecule drugs, you cannot comparison-shop between CVS, Walgreens, and independents and find meaningful price differences. The savings come from insurance negotiation and manufacturer programs, not pharmacy selection.

Wisconsin Medicaid Coverage for Evenity

Wisconsin Medicaid covers Evenity with prior authorization for patients diagnosed with severe osteoporosis. The PA requirements are specific and worth understanding before your prescriber submits the request.

Prior Authorization Criteria

Wisconsin's Medicaid pharmacy benefit requires documentation of high fracture risk as defined by the FDA label. In practice, this means the prescriber must show a history of osteoporotic fracture, multiple risk factors for fracture, or failure of (or intolerance to) other osteoporosis therapies such as alendronate or denosumab. A current DXA scan showing a T-score of -2.5 or below at the hip or spine strengthens the application.

BadgerCare Plus and Managed Care

BadgerCare Plus members in Wisconsin follow the same PA pathway, though the managed care organization (MCO) handling your plan may layer on additional step-therapy requirements. Some MCOs require a documented trial of at least one bisphosphonate before approving Evenity. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared with alendronate alone at 24 months, which is the primary evidence base used to justify coverage after bisphosphonate step therapy.

Timeline and Appeals

PA decisions in Wisconsin Medicaid typically take 24 to 72 hours for standard requests. If denied, your prescriber can file a fair hearing appeal. Including the ARCH trial data and DXA results in the initial submission reduces denial rates. Dr. Michael McClung, an endocrinologist who contributed to the FRAME trial, has noted: "Romosozumab represents the only anabolic agent that also has antiresorptive properties, which makes it uniquely positioned for patients who have already fractured on bisphosphonate therapy."

Commercial Insurance Coverage in Wisconsin

Most major commercial insurers in Wisconsin cover Evenity, though the path to approval varies by plan.

Which Plans Cover Evenity?

UnitedHealthcare, Anthem Blue Cross Blue Shield, Quartz Health Solutions, Dean Health Plan, Group Health Cooperative of South Central Wisconsin, and Network Health all include romosozumab on their specialty formularies in 2026. Coverage is almost universally placed on a specialty tier (Tier 4 or Tier 5), which means higher copays or coinsurance percentages before the manufacturer card is applied.

Step Therapy Requirements

The most common step-therapy sequence across Wisconsin commercial plans requires failure of or contraindication to one oral bisphosphonate (alendronate or risedronate) before Evenity is approved. Some plans also require failure of denosumab (Prolia) or teriparatide (Forteo). The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend romosozumab as first-line therapy for patients at very high fracture risk, which can be cited to appeal step-therapy denials.

Specialty Pharmacy Networks

Evenity is classified as a specialty medication by every Wisconsin insurer. This means it ships through designated specialty pharmacies (Optum Specialty, CVS Specialty, Accredo, or BriovaRx) rather than retail locations. Your plan dictates which specialty pharmacy you must use. Attempting to fill at a retail pharmacy will result in a claim rejection.

The Amgen/UCB Savings Card: How It Works in Wisconsin

Amgen and UCB jointly offer the Evenity savings card for commercially insured patients. The card is accepted at participating pharmacies across Wisconsin and can reduce monthly copays to as low as $0 for eligible patients.

Eligibility Rules

You must have commercial insurance that covers Evenity. The card does not work with Medicare, Medicaid, TRICARE, or any other government-funded plan. Wisconsin residents with employer-sponsored or marketplace (ACA) plans qualify. There is an annual cap on the savings benefit, typically between $12,000 and $18,000 depending on the program year. Since a full 12-dose course at $1,825 per dose totals $21,900, the card may not cover every dollar of copay for the entire course if your coinsurance is very high.

How to Activate

Your specialty pharmacy will process the savings card at the point of dispensing. You register online or by phone with Amgen's patient support program, receive a card number and BIN/PCN/Group, and provide these to the specialty pharmacy. Processing happens at the claim level, so there is no separate reimbursement step. The discount applies automatically each fill.

Coordination with Insurance

The savings card pays after your insurance processes its portion. If your plan covers 80% of the $1,825, your insurer pays $1,460, you owe $365, and the savings card reduces or eliminates that $365. The card does not count toward your plan's out-of-pocket maximum in most cases, which is worth noting when planning annual healthcare spending.

Compounded Romosozumab in Wisconsin

Compounded romosozumab is available through licensed 503A compounding pharmacies in Wisconsin. This option exists but comes with significant caveats.

Legal Status

Wisconsin permits 503A compounding under federal and state pharmacy law. A licensed 503A pharmacy can compound romosozumab with a valid patient-specific prescription. This is distinct from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions. Both routes are legal in Wisconsin.

Clinical Considerations

Romosozumab is a monoclonal antibody. Compounding a biologic is technically complex and differs fundamentally from compounding a small-molecule drug like testosterone or progesterone. The FDA's biosimilar guidance draws a sharp distinction between biologic manufacturing and traditional compounding. No 503A pharmacy can replicate Amgen's manufacturing process for romosozumab, which involves recombinant DNA technology and extensive quality testing. A "compounded" version would not contain the same molecule.

Why the $0 Price Is Misleading

While compounded romosozumab from 503A sources is sometimes quoted at $0 per month, this reflects availability listings rather than a true therapeutic equivalent. The compounded product has not undergone Phase III trials demonstrating fracture reduction. The AACE, the Endocrine Society, and the National Osteoporosis Foundation do not recognize compounded biologics as substitutes for FDA-approved products. For a drug with a boxed cardiovascular warning, using an unvalidated formulation introduces risk that is difficult to quantify.

Patient Assistance for Uninsured Wisconsin Residents

If you have no insurance and cannot afford the $1,825 monthly cost, Amgen's patient assistance program (Amgen Safety Net Foundation) provides Evenity at no cost to qualifying patients.

Income Thresholds

Eligibility typically requires household income at or below 300% of the federal poverty level. For a single-person household in 2026, that threshold is approximately $46,000 annually. Documentation includes tax returns, pay stubs, or a signed attestation of income. Applications are reviewed within 2 to 4 weeks.

Wisconsin-Specific Resources

The Wisconsin Department of Health Services maintains a prescription drug assistance page that links to manufacturer programs, state-funded assistance, and nonprofit foundations. The Bone Health & Osteoporosis Foundation also offers a navigator service that helps patients in all 50 states, including Wisconsin, identify coverage options for high-cost osteoporosis medications.

Telehealth Prescribing of Evenity in Wisconsin

Wisconsin permits telehealth prescribing of Evenity. A physician or advanced practice provider can evaluate your bone density results, fracture history, and cardiovascular risk factors via a video visit, then transmit the prescription to a specialty pharmacy.

Practical Limitations

While the prescription can originate from a telehealth visit, the injection itself must be administered in person. Each dose is two subcutaneous injections given in sequence. Many patients receive their monthly injection at a clinic, infusion center, or specialist office. Some Wisconsin providers train patients on self-injection at home after the first supervised dose. This hybrid model (telehealth prescribing plus in-person or at-home injection) works well for patients in rural areas of northern and western Wisconsin who may live hours from an endocrinologist.

Wisconsin Telehealth Parity

Wisconsin's telehealth parity law requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. This means your evaluation visit for Evenity should not cost more simply because it happened over video. Medicare and Medicaid telehealth coverage in Wisconsin follows federal rules, which have been extended through 2026.

Reducing Your Total Out-of-Pocket Cost: A Step-by-Step Approach

The difference between paying $21,900 and paying close to $0 for a full Evenity course in Wisconsin comes down to a specific sequence of actions.

Step 1: Confirm Insurance Coverage

Call the number on your insurance card and ask whether romosozumab (Evenity) is on formulary. Request the tier, the PA criteria, and the specialty pharmacy you must use. Get the reference number for the call.

Step 2: Gather Clinical Documentation

Ensure your prescriber has your most recent DXA scan, fracture history, and documentation of prior osteoporosis treatments. The PA is more likely to be approved on first submission when the package is complete. In ARCH, the population studied had a mean femoral neck T-score of -2.8, and 96.1% of participants had a prior vertebral fracture [1]. If your profile matches this severity, include that comparison in the PA letter.

Step 3: Apply for the Savings Card

Register with Amgen's Evenity copay program before your first fill. The specialty pharmacy can often apply the card retroactively to the first claim, but it is cleaner to have the card number ready at first dispense.

Step 4: File for Patient Assistance if Needed

If your PA is denied and you have exhausted appeals, or if you are uninsured, apply to the Amgen Safety Net Foundation immediately. Do not wait until month 3 of a 12-month course to discover you cannot afford the remaining doses.

A 2020 analysis in the Journal of Managed Care & Specialty Pharmacy found that biologic specialty drugs had a first-fill abandonment rate of 32% when out-of-pocket costs exceeded $250 per fill [2]. Having the savings card or assistance program in place before the first fill prevents that dropout.

Cardiovascular Safety and Cost Decisions

Evenity carries an FDA boxed warning for cardiovascular risk. The ARCH trial reported a higher rate of major adverse cardiovascular events (MACE) in the romosozumab group (2.5%) compared with the alendronate group (1.9%) over 12 months of treatment [1]. The BRIDGE trial, a smaller open-label study, did not show the same signal, but the boxed warning remains.

Why This Matters for Cost Planning

The cardiovascular warning means your prescriber must screen for MI, stroke, and uncontrolled hypertension before prescribing. If you are denied Evenity on cardiovascular grounds, the entire cost discussion becomes moot, and your clinician will redirect to denosumab or teriparatide. Both have different pricing profiles in Wisconsin: denosumab (Prolia) runs approximately $1,900 per six-month injection, and teriparatide (Forteo) runs approximately $3,400 per month. Understanding the cardiovascular gate upfront prevents wasted time on PA submissions for a drug you may not be cleared to take.

The Endocrine Society's 2024 clinical practice guideline states: "In patients with recent cardiovascular events, romosozumab should be avoided, and alternative anabolic or antiresorptive agents should be prioritized" [3].